Literature DB >> 34003413

Coronavirus Disease-19 Vaccines Best Reflect Effective Pharmaceuticals.

Marco Cosentino1, Marco Ferrari2, Franca Marino2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34003413      PMCID： PMC8129696          DOI： 10.1007/s11481-021-09998-z

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN： 1557-1890            Impact factor:   4.147


× No keyword cloud information.
  8 in total

Review 1.  Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.

Authors:  John J Suschak; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2019-10-07       Impact factor: 3.452

2.  Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.

Authors:  Norbert Pardi; Steven Tuyishime; Hiromi Muramatsu; Katalin Kariko; Barbara L Mui; Ying K Tam; Thomas D Madden; Michael J Hope; Drew Weissman
Journal:  J Control Release       Date:  2015-08-08       Impact factor: 9.776

Review 3.  Nonintegrating Gene Therapy Vectors.

Authors:  Takis Athanasopoulos; Mustafa M Munye; Rafael J Yáñez-Muñoz
Journal:  Hematol Oncol Clin North Am       Date:  2017-10       Impact factor: 3.722

4.  Evaluation of flavonoids as 2019-nCoV cell entry inhibitor through molecular docking and pharmacological analysis.

Authors:  Deep Bhowmik; Rajat Nandi; Amresh Prakash; Diwakar Kumar
Journal:  Heliyon       Date:  2021-03-14

Review 5.  SARS-CoV-2 vaccines: Lights and shadows.

Authors:  Fabio Angeli; Antonio Spanevello; Gianpaolo Reboldi; Dina Visca; Paolo Verdecchia
Journal:  Eur J Intern Med       Date:  2021-04-30       Impact factor: 7.749

6.  The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2.

Authors:  Liang Chen; Xiangjie Li; Mingquan Chen; Yi Feng; Chenglong Xiong
Journal:  Cardiovasc Res       Date:  2020-05-01       Impact factor: 10.787

Review 7.  ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome.

Authors:  Christian A Devaux; Jean-Marc Rolain; Didier Raoult
Journal:  J Microbiol Immunol Infect       Date:  2020-05-06       Impact factor: 4.399

Review 8.  Immunological considerations for COVID-19 vaccine strategies.

Authors:  Mangalakumari Jeyanathan; Sam Afkhami; Fiona Smaill; Matthew S Miller; Brian D Lichty; Zhou Xing
Journal:  Nat Rev Immunol       Date:  2020-09-04       Impact factor: 53.106
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.